BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2551841)

  • 1. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study.
    Lad TE; Blough RR; Evrard M; Shevrin DP; Cobleigh MA; Johnson CM; Hange P
    Invest New Drugs; 1989 Jul; 7(2-3):223-4. PubMed ID: 2551841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
    Ettinger DS; Finkelstein DM; Abeloff MD; Chang YC; Smith TJ; Oken MM; Ruckdeschel JC
    Invest New Drugs; 1990 May; 8(2):183-5. PubMed ID: 2166720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of spirogermanium in patients with advanced colorectal carcinoma.
    Ajani JA; Faintuch JS; McClure RK; Levin B; Boman BM; Krakoff IH
    Invest New Drugs; 1986; 4(4):383-5. PubMed ID: 3583645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of spirogermanium in advanced large bowel cancer. An Eastern Cooperative Oncology Group study.
    Pandya KJ; Kramar A; Asbury RF; Haller DG
    Am J Clin Oncol; 1988 Aug; 11(4):496-8. PubMed ID: 3407630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
    Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
    Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of spirogermanium in patients with advanced malignant lymphoma.
    Sessa C; ten Bokkel Huinik W; Clavel M; Lev LM; Joss RA; Renard J; Cavalli F
    Invest New Drugs; 1989 Jul; 7(2-3):219-22. PubMed ID: 2793376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of oral spirogermanium.
    Harvey J; McFadden M; Smith FP; Joubert L; Schein PS
    Invest New Drugs; 1990 Feb; 8(1):53-6. PubMed ID: 2345069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
    Dhingra HM; Umsawasdi T; Chiuten DF; Murphy WK; Holoye PY; Spitzer G; Valdivieso M
    Cancer Treat Rep; 1986 May; 70(5):673-4. PubMed ID: 3708617
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
    Williamson SK; Slavik M
    Invest New Drugs; 1991 Feb; 9(1):49-52. PubMed ID: 2026484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of spirogermanium and vindesine in malignant glioma.
    Alavi JB; Schoenfeld D; Skeel RT; Kirkwood R; Tsung L; Marsh JC
    Am J Clin Oncol; 1989 Feb; 12(1):8-10. PubMed ID: 2912024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of spirogermanium given daily.
    Legha SS; Ajani JA; Bodey GP
    J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
    Slavik M; Blanc O; Davis J
    Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
    Weiselberg L; Budman DR; Schulman P; Vinciguerra V; Degnan TJ; Pasmantier M
    Cancer Treat Rep; 1982 Aug; 66(8):1675-6. PubMed ID: 7201885
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
    Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phase I trial of spirogermanium administered on a continuous infusion schedule.
    Woolley PV; Ahlgren JD; Byrne PJ; Priego VM; Schein PS
    Invest New Drugs; 1984; 2(3):305-9. PubMed ID: 6511236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
    Budman DR; Schulman P; Vinciguerra V; Degnan TJ
    Cancer Treat Rep; 1982 Jan; 66(1):173-5. PubMed ID: 7053254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
    Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
    Invest New Drugs; 1985; 3(3):303-5. PubMed ID: 4066224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of spirogermanium for treatment of advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Treat Rep; 1983 Feb; 67(2):189-90. PubMed ID: 6825129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.